Global Autoimmune Disease Diagnosis Market Overview:
According to SPER Market Research, the Global Autoimmune Disease Diagnosis Market is estimated to reach USD 8.36 billion by 2030 with a CAGR of 7.8%. A body's aberrant immune response that results in the development of antibodies that target its own cells and tissues, causing degeneration and the elimination of healthy tissues, is referred to as an autoimmune illness. Multiple sclerosis, type 1 diabetes, and rheumatoid arthritis are three of the almost 80 autoimmune disorders that are prevalent globally.
Autoantibody, antinuclear, complete blood count, C-reactive protein, and erythrocyte sedimentation rate tests are used to identify the autoimmune disease. Growing incidences of conditions like rheumatoid arthritis and Hashimoto's thyroiditis, as well as the existence of supportive governmental regulations, will have a significant impact on the market growth for autoimmune disease diagnostics.
Impact of COVID-19 on the Global Autoimmune Disease Diagnosis Market:
An international stress test has been created by the COVID-19 epidemic. Worldwide, the COVID-19 illness has affected 545 million individuals. According to the most recent data from the Worldometers, the death toll has reached 6,464,291 globally (as of August 18, 2022). The number is continually increasing, and it's still hard to determine how long the epidemic will last. Global concern and a sense of urgency have been brought on by the COVID-19 epidemic. To combat the coronavirus, several nations have implemented rigorous measures, including mass vaccination campaigns, social withdrawal, the usage of masks, etc. Manufacturers in the autoimmune disease diagnostics market are concentrating on creating cutting-edge technologies for performing the most tests in the shortest amount of time. As a result, we anticipate that physicians will notice an increase in the number of patients, which will fuel the expansion of the autoimmune disorders diagnostics market.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2019-2030 |
| Base year considered | 2021 |
| Forecast period | 2022-2030 |
| Segments covered | By Product, By End User, By Test Type
|
| Geographies covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
| Companies Covered | Abbott Laboratories Inc., Bio-Rad Laboratories, bioMérieux SA, Danahar Corp., F. Hoffmann-La Roche AG, Labcorp Acquires Assets of Myriad Genetics, Merck and co. Acquired Pandion Therapeutics, Oncimmune Acquires Protagen Diagnostics, PerkinElmer Acquires Euroimmune, Quest Diagnostics Acquires Labtech Diagnostics, Sebia Acquires ORGENTEC Diagnostika, Siemens Healthineers, Thermo Fisher Scientific Inc.
|
Global Autoimmune Disease Diagnosis Market Segmentation:
By Product: Based on the Product, Global Autoimmune Disease Diagnosis Market is segmented as; Consumables and Assay Kits, Instruments.
By End User: Based on the End User, Global Autoimmune Disease Diagnosis Market is segmented as; Clinical Laboratories and Hospitals.
By Test Type: Based on the Test Type, Global Autoimmune Disease Diagnosis Market is segmented as; Routine Laboratory Tests, Autoantibodies Tests, Immunologic Tests and Other Tests.
By Region: Europe and Asia held the highest share of the worldwide Global Autoimmune Disease Diagnosis Market, but it is predicted to develop slowly throughout the forecast period. Because of its size, it remains one of the most important marketplaces for Autoimmune Disease Diagnosis companies.
1. Introduction
1.1 Scope of the report
1.2 Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.2.2 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1 Driver, Restraint, Opportunity, and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 COVID-19 Impacts on Global Autoimmune Disease Diagnosis Market
5. Market variables and outlook
5.1 SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2 PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3 PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4 Heat map analysis
6. Global Autoimmune Disease Diagnosis Market, By Product, 2019-2030 (USD Million)
6.1 Consumables and Assay Kits
6.2 Instruments
7. Global Autoimmune Disease Diagnosis Market, By End User, 2019-2030 (USD Million)
7.1 Clinical Laboratories
7.2 Hospitals
7.3 Others
8. Global Autoimmune Disease Diagnosis Market, By Test Type, 2019-2030 (USD Million)
8.1 Routine Laboratory Tests
8.2 Autoantibodies Tests
8.3 Immunologic Tests
8.4 Other Tests
9. Global Autoimmune Disease Diagnosis Market, By Region, 2019-2030 (USD Million)
9.1 North America
9.1.1 United States
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 United Kingdom
9.2.3 France
9.2.4 Italy
9.2.5 Spain
9.2.6 Rest of Europe
9.3 Asia-Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Australia
9.3.5 South Korea
9.3.6 Rest of Asia-Pacific
9.4 South America
9.4.1 Brazil
9.4.2 Argentina
9.4.3 Rest of South America
9.5 Middle East & Africa
9.5.1 Kingdom of Saudi Arabia
9.5.2 United Arab Emirates
9.5.3 Rest of Middle East & Africa
10. Company Profiles
10.1 Abbott Laboratories
10.1.1 Company details
10.1.2 Financial outlook
10.1.3 Product summary
10.1.4 Recent developments
10.2 Bio-Rad Laboratories Inc.
10.2.1 Company details
10.2.2 Financial outlook
10.2.3 Product summary
10.2.4 Recent developments
10.3 bioMérieux SA
10.3.1 Company details
10.3.2 Financial outlook
10.3.3 Product summary
10.3.4 Recent developments
10.4 Danaher Corp.
10.4.1 Company details
10.4.2 Financial outlook
10.4.3 Product summary
10.4.4 Recent developments
10.5 F. Hoffmann-La Roche AG
10.5.1 Company details
10.5.2 Financial outlook
10.5.3 Product summary
10.5.4 Recent developments
10.6 Labcorp Acquires Assets of Myriad Genetics
10.6.1 Company details
10.6.2 Financial outlook
10.6.3 Product summary
10.6.4 Recent developments
10.7 Merck & Co. Acquired Pandion Therapeutics
10.7.1 Company details
10.7.2 Financial outlook
10.7.3 Product summary
10.7.4 Recent developments
10.8 Oncimmune Acquires Protagen Diagnostics
10.8.1 Company details
10.8.2 Financial outlook
10.8.3 Product summary
10.8.4 Recent developments
10.9 PerkinElmer Acquires Euroimmune
10.9.1 Company details
10.9.2 Financial outlook
10.9.3 Product summary
10.9.4 Recent developments
10.10 Quest Diagnostics Acquires Labtech Diagnostics
10.10.1 Company details
10.10.2 Financial outlook
10.10.3 Product summary
10.10.4 Recent developments
10.11 Sebia Acquires ORGENTEC Diagnostika
10.11.1 Company details
10.11.2 Financial outlook
10.11.3 Product summary
10.11.4 Recent developments
10.12 Siemens Healthineers
10.12.1 Company details
10.12.2 Financial outlook
10.12.3 Product summary
10.12.4 Recent developments
10.13 Thermo Fisher Scientific Inc.
10.13.1 Company details
10.13.2 Financial outlook
10.13.3 Product summary
10.13.4 Recent developments
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
